Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer

Song,Zhou; Wei,Bo; Lu,Canrong; Li,Peiyu; Chen,Lin

doi:10.3892/ol.2017.6538

Glutaminase sustains cell survival via the regulation of glycolysis and glutaminolysis in colorectal cancer

Authors:
- Zhou Song
- Bo Wei
- Canrong Lu
- Peiyu Li
- Lin Chen
View Affiliations

Affiliations: Department of General Surgery, General Hospital of Chinese People's Liberation Army, Beijing 100853, P.R. China
Published online on: July 7, 2017 https://doi.org/10.3892/ol.2017.6538
Pages: 3117-3123

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cells remodel their metabolic programs towards aerobic glycolysis and elevated glutaminolysis to meet the requirement s of rapid proliferation. Understanding how cells sense and adapt to these changes may provide new targets for therapeutic intervention. Deamination of glutamine to glutamate by glutaminase (GLS1) is an essential step in glutaminolysis. The present study revealed that the loss of GLS1 expression by RNA interference or inhibitor decreased the proliferation and viability of colorectal cancer (CRC) cells. The abrogation of GLS1 function notably inhibited glutaminolysis and aerobic glycolysis, which resulted in the decrease of internal ATP levels and an increase in cell death. In addition, GLS1 expression was significantly elevated in CRC tissues in comparison with adjacent normal tissues (P<0.001), which is associated with the cell differentiation status and tumor node metastasis stage. In conclusion, the present study defined a key role of GLS1 in coupling glutaminolysis with elevated glucose uptake and consequently the growth of colon cancer cells. Due to the functional importance of GLS1 in regulating cell metabolism, it was proposed that GLS1 may serve as a target for colorectal cancer therapy.

View Figures

View References

1	Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117. 2014. View Article : Google Scholar : PubMed/NCBI
2	DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
3	Dang CV: Links between metabolism and cancer. Genes Dev. 26:877–890. 2012. View Article : Google Scholar : PubMed/NCBI
4	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wise DR and Thompson CB: Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci. 35:427–433. 2010. View Article : Google Scholar : PubMed/NCBI
7	Daye D and Wellen KE: Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 23:362–369. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hensley CT, Wasti AT and DeBerardinis RJ: Glutamine and cancer: Cell biology, physiology, and clinical opportunities. J Clin Invest. 123:3678–3684. 2013. View Article : Google Scholar : PubMed/NCBI
9	Curthoys NP and Watford M: Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 15:133–159. 1995. View Article : Google Scholar : PubMed/NCBI
10	Mates JM, Segura JA, Martín-Rufian M, Campos-Sandoval JA, Alonso FJ and Márquez J: Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 13:514–534. 2013. View Article : Google Scholar : PubMed/NCBI
11	Huang F, Zhang Q, Ma H, Lv Q and Zhang T: Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol. 7:1093–1100. 2014.PubMed/NCBI
12	Pan T, Gao L, Wu G, Shen G, Xie S, Wen H, Yang J, Zhou Y, Tu Z and Qian W: Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem Biophys Res Commun. 456:452–458. 2015. View Article : Google Scholar : PubMed/NCBI
13	Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al: Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 13:890–901. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kaadige MR, Elgort MG and Ayer DE: Coordination of glucose and glutamine utilization by an expanded Myc network. Transcription. 1:36–40. 2010. View Article : Google Scholar : PubMed/NCBI
15	Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
16	Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, et al: Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 125:1591–1602. 2015. View Article : Google Scholar : PubMed/NCBI
17	Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, Turay AM and Frauwirth KA: Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 185:1037–1044. 2010. View Article : Google Scholar : PubMed/NCBI
18	Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, Hansen JC and Curthoys NP: Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 406:407–414. 2007. View Article : Google Scholar : PubMed/NCBI
19	Stalnecker CA, Ulrich SM, Li Y, Ramachandran S, McBrayer MK, DeBerardinis RJ, Cerione RA and Erickson JW: Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci USA. 112:394–399. 2015. View Article : Google Scholar : PubMed/NCBI
20	Williams DM, Schachter J, Drutz DJ and Sumaya CV: Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J Infect Dis. 143:238–241. 1981. View Article : Google Scholar : PubMed/NCBI
21	Chu D, Zhang Z, Li Y, Wu L and Zhang J, Wang W and Zhang J: Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther. 10:47–56. 2011. View Article : Google Scholar : PubMed/NCBI
22	Kaadige MR, Looper RE, Kamalanaadhan S and Ayer DE: Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci USA. 106:14878–14883. 2009. View Article : Google Scholar : PubMed/NCBI
23	Tennant DA, Durán RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 10:267–277. 2010. View Article : Google Scholar : PubMed/NCBI
24	Richard SM and Martinez Marignac VL: Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition. J Cancer Res Ther. 11:336–340. 2015. View Article : Google Scholar : PubMed/NCBI